Transdermal microarrayed electroporation for enhanced cancer immunotherapy based on DNA vaccination

Area of Science:

• Biomedical Engineering
• Immunology
• Materials Science

Background:

• Nucleic acid vaccines show promise but require efficient in vivo gene delivery.
• Current methods for DNA delivery and electroporation face limitations in efficacy and local targeting.
• Developing advanced delivery systems is crucial for enhancing cancer immunotherapy.

Purpose of the Study:

• To develop a hydrogel-based organic electronic device (μEPO) for transdermal nucleic acid delivery and in vivo electroporation.
• To achieve efficient one-step DNA transfection of subcutaneous antigen-presenting cells (APCs) for cancer immunotherapy.
• To demonstrate the efficacy of the μEPO technique in activating antigen-specific immune responses and inhibiting tumor growth.

Main Methods:

• Fabrication of a hydrogel-based organic electronic device (μEPO) with microneedle electrodes containing dry DNA.
• Application of the μEPO device for transdermal delivery and electroporation of DNA into skin cells.
• Evaluation of the immune response and anti-tumor efficacy in a cancer vaccine model using ovalbumin (OVA)-DNA.

Main Results:

• The μEPO device achieved in vivo transfection of over 50% of cells in the epidermal and upper dermal layers.
• Transdermal delivery of OVA-DNA using μEPO induced robust cellular and humoral immune responses, including IFN-γ+ cytotoxic T lymphocytes.
• The μEPO approach demonstrated over 10-fold dose sparing compared to intramuscular injection and effectively inhibited tumor growth.

Conclusions:

• The μEPO device offers an efficient and localized method for transdermal DNA delivery and electroporation.
• This technology significantly enhances DNA vaccination strategies for cancer immunotherapy by boosting antigen-specific immunity.
• The μEPO technique presents a promising alternative to conventional injection methods for nucleic acid-based therapies.